As global regulators tighten standards, India’s pharma industry is moving beyond its old cost advantage toward tighter compliance, quality systems, and regulatory trust. With scrutiny rising across target markets, exporters face higher expectations on documentation, testing, and manufacturing practices, pushing the $30 billion export engine to recalibrate its playbook for long term access.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
